Related Experiment Videos
Post-hospitalization management of high-risk coronary patients
1Division of Cardiology, University of Utah, LDS Hospital, Salt Lake City 84143, USA.
Insights
Secondary prevention strategies, including medications like statins and aspirin, significantly reduce mortality in patients with coronary atherosclerosis. Lifestyle changes and improved patient care also play a vital role in preventing adverse outcomes.
Area of Science:
- Cardiology
- Vascular Biology
- Preventive Medicine
Background:
- Coronary atherosclerosis plaque rupture is a primary cause of acute coronary syndromes, leading to significant morbidity and mortality.
- Plaque rupture is associated with fibrous cap thickness and inflammation, highlighting the need for effective secondary prevention strategies.
Purpose of the Study:
- To review the efficacy of secondary prevention strategies for coronary atherosclerosis.
- To emphasize the importance of overlooked secondary prevention measures in reducing mortality and morbidity.
Main Methods:
- Review of existing studies on secondary prevention interventions for coronary atherosclerosis.
- Analysis of the impact of medications, lifestyle modifications, and patient management strategies on patient outcomes.
Main Results:
- Aspirin demonstrated a 30-50% reduction in mortality; beta blockers showed a 15-50% reduction post-myocardial infarction.
- Angiotensin-converting enzyme (ACE) inhibitors significantly reduced death risk in patients with coronary artery disease.
- Statins provided substantial mortality reduction (50%) independent of baseline lipid levels, potentially due to anti-inflammatory effects.
Conclusions:
- Secondary prevention is crucial for managing coronary atherosclerosis and improving patient survival.
- Medications including aspirin, beta blockers, ACE inhibitors, and statins are highly effective in reducing mortality.
- Comprehensive secondary prevention strategies, encompassing lifestyle changes and enhanced patient care, are vital for long-term outcomes.
Abstract:
The major cause of morbidity and mortality associated with coronary atherosclerosis is plaque rupture, which often results in one of the acute coronary syndromes: unstable angina, non-Q-wave myocardial infarction (MI), or Q-wave MI. Plaque rupture may be attributable to the thickness of the overlying fibrous cap; thinner plaques are more likely to rupture. It appears that the presence of inflammation is a significant contributor to rupture. Acute-phase treatments are highly efficacious, but secondary prevention, often overlooked, also is life-saving. Diet, exercise, and medications are the interventions available for secondary prevention. Four classes of medications--aspirin, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins)--are also used in this setting with a high degree of success in reducing mortality and morbidity. Numerous studies have demonstrated a 30-50% reduction in mortality with aspirin. The reduction in mortality achieved with beta blockers in studies of patients after myocardial infarction are 15-50%. ACE inhibitors significantly reduce the risk of death from myocardial infarction in patients with coronary artery disease with or without myocardial infarction. Statins are beneficial even in patients whose cholesterol level is low to normal. Patients who were discharged on a statin showed a 50% reduction in mortality over those who did not receive statin therapy independent of lipid level. C-reactive protein, a marker of inflammation, is predictive of mortality, as are age and ejection fraction. Statins may be anti-inflammatory in addition to their lipid-lowering effect. Secondary-prevention strategies such as case management, electronic discharge prompting, better communication between referring physicians and cardiologists, and patient education may also have positive effects on after-discharge morbidity and mortality.